Amoxycillin 200mg + Clavulanic 28.50mg with Water
STRIKEMOX™ CV Dry Syrup is a paediatric oral suspension delivering amoxycillin and clavulanic acid in a palatable, reconstitutable liquid form for children who cannot swallow tablets. Amoxycillin is a broad-spectrum aminopenicillin that kills susceptible bacteria by binding to penicillin-binding proteins (PBPs) on the bacterial cell membrane. This irreversible binding inhibits transpeptidase activity — the enzyme responsible for the final cross-linking of peptidoglycan — causing structural failure of the bacterial cell wall, osmotic imbalance, and bacterial lysis.
Clavulanic Acid extends the antibacterial spectrum by irreversibly inhibiting beta-lactamase enzymes produced by resistant organisms. Beta-lactamases are the most common mechanism of bacterial resistance to penicillins and are particularly prevalent among H. influenzae, M. catarrhalis, and S. aureus strains commonly isolated in paediatric ENT and respiratory infections. By permanently inactivating these enzymes, clavulanic acid protects amoxycillin from enzymatic degradation and restores its bactericidal efficacy.
STRIKEMOX™ CV Dry Syrup is indicated for paediatric bacterial infections across ENT, respiratory, urinary, and skin indications.
Acute Otitis Media: First-line treatment in children above 3 months where beta-lactamase-producing H. influenzae and M. catarrhalis are responsible for a significant proportion of cases.
Acute Bacterial Sinusitis: Paediatric sinusitis with significant beta-lactamase-producing organism involvement.
Community-Acquired Pneumonia: Mild-to-moderate community-acquired pneumonia in children managed in the outpatient setting.
Urinary Tract Infections: E. coli and Klebsiella UTIs in children above 3 months.
Tonsillitis and Pharyngitis: Beta-haemolytic streptococcal pharyngitis, particularly in recurrent or treatment-resistant cases.
Skin Infections: Impetigo, cellulitis, and infected eczema caused by S. aureus and Streptococcus species.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
The paediatric co-amoxiclav dry syrup segment is one of the highest-volume categories in Indian paediatric prescribing. Acute otitis media affects nearly every child multiple times before the age of 5, and amoxycillin-clavulanate is the recommended treatment in the majority of cases above the age of 3 months. DPCO pricing ensures every patient family can access the full 7 to 10 day course without cost-driven early discontinuation. Seclis Labs' manufacturing partners produce this dry syrup under WHO-GMP conditions with rigorous content uniformity and reconstitution testing.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.